Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of "Hold" by Analysts

Key Points

• Analyst consensus is “Hold” for Xeris Biopharma, with four buys, two holds and one sell among seven analysts. The average 12-month price target is $12.80, while recent targets ranged from $12 to $16.
• Xeris reported quarterly revenue of $92.1 million, exceeding estimates of $90.12 million, but its adjusted loss of $0.18 per share missed the expected $0.01 profit.
• The stock opened at $8.20 and trades within a $5.25–$10.08 one-year range. Insiders sold roughly $1.85 million in shares over the past 90 days, while institutional investors own 42.75% of the company.

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $12.80.

XERS has been the topic of several recent research reports. Leerink Partners upped their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an "outperform" rating in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday. Barclays boosted their price target on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an "overweight" rating in a research report on Thursday, August 20th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th.

Xeris Biopharma Stock Performance

Shares of XERS opened at $8.20 on Monday. The firm has a market cap of $1.50 billion, a PE ratio of -74.55 and a beta of 0.70. The stock's fifty day moving average price is $8.33 and its two-hundred day moving average price is $7.07. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma has a 1 year low of $5.25 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The firm had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. On average, equities research analysts forecast that Xeris Biopharma will post 0.07 EPS for the current year.

Insider Activity at Xeris Biopharma

In other news, insider Steven Pieper sold 27,600 shares of the firm's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $8.52, for a total value of $235,152.00. Following the completion of the transaction, the insider directly owned 1,366,053 shares of the company's stock, valued at $11,638,771.56. This trade represents a 1.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 90,000 shares of the firm's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the transaction, the insider directly owned 1,691,126 shares of the company's stock, valued at $13,579,741.78. The trade was a 5.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 224,998 shares of company stock worth $1,847,219. Corporate insiders own 4.35% of the company's stock.

Institutional Trading of Xeris Biopharma

A number of institutional investors have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC bought a new stake in shares of Xeris Biopharma during the second quarter valued at about $74,000. Allworth Financial LP lifted its holdings in shares of Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company's stock worth $34,000 after buying an additional 2,000 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Xeris Biopharma in the second quarter valued at approximately $314,000. Corient Private Wealth LP bought a new position in shares of Xeris Biopharma in the second quarter valued at approximately $1,458,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Xeris Biopharma during the second quarter valued at approximately $89,000. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc NASDAQ: XERS is a specialty pharmaceutical company focused on developing and commercializing therapies using proprietary formulation and drug-delivery technologies. Its platforms, including XeriSol and XeriJect, are designed to enable liquid or ready-to-use formulations of medicines that may otherwise require refrigeration, reconstitution, or administration by a healthcare professional.

The company's commercial products include Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia; Keveyis (dichlorphenamide), an oral therapy for primary periodic paralysis; and Recorlev (levoketoconazole), an oral treatment for endogenous hypercortisolemia in adults with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.